BridgeBio Pharma (BBIO) Interest Expenses (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Interest Expenses data on file, last reported at $20.3 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 12.7% year-over-year to $20.3 million; the trailing twelve-month figure through Mar 2026 stood at $77.1 million (down 25.53% YoY), and the FY2025 full-year result was $968.0 million, up 33.09% from the prior year.
• Interest Expenses rose to $20.3 million in Q1 2026, from $11.6 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $205.3 million in Q2 2025 to a low of $11.6 million in Q4 2025.
• A 5-year average of $38.6 million and a median of $22.1 million in 2023 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses sank 80.79% in 2022 and surged 221.02% in 2024, its largest moves.
• Tracing BBIO's Interest Expenses over 5 years: stood at $32.9 million in 2022, then retreated by 7.3% to $30.5 million in 2023, then declined by 28.2% to $21.9 million in 2024, then plunged by 46.8% to $11.6 million in 2025, then jumped by 74.6% to $20.3 million in 2026.
• Business Quant data shows BBIO's Interest Expenses at $20.3 million in Q1 2026, $11.6 million in Q4 2025, and $62.0 million in Q3 2025.